ATE183196T1 - Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen - Google Patents

Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen

Info

Publication number
ATE183196T1
ATE183196T1 AT94902266T AT94902266T ATE183196T1 AT E183196 T1 ATE183196 T1 AT E183196T1 AT 94902266 T AT94902266 T AT 94902266T AT 94902266 T AT94902266 T AT 94902266T AT E183196 T1 ATE183196 T1 AT E183196T1
Authority
AT
Austria
Prior art keywords
fibronectin
collagen
binding proteins
peptide inhibitors
related collagen
Prior art date
Application number
AT94902266T
Other languages
English (en)
Inventor
David D Roberts
Henry C Krutzch
John M Sipes
Neng-Hua Guo
Eric Negre
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE183196T1 publication Critical patent/ATE183196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94902266T 1992-11-10 1993-11-09 Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen ATE183196T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/973,235 US5491130A (en) 1992-11-10 1992-11-10 Peptide inhibitors of fibronectin and related collagen-binding proteins

Publications (1)

Publication Number Publication Date
ATE183196T1 true ATE183196T1 (de) 1999-08-15

Family

ID=25520653

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94902266T ATE183196T1 (de) 1992-11-10 1993-11-09 Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen

Country Status (8)

Country Link
US (2) US5491130A (de)
EP (1) EP0669937B1 (de)
JP (2) JP3789931B2 (de)
AT (1) ATE183196T1 (de)
AU (1) AU683234B2 (de)
CA (1) CA2148383A1 (de)
DE (1) DE69326016T2 (de)
WO (1) WO1994011395A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2157981T3 (es) * 1993-03-12 2001-09-01 Xoma Technology Ltd Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad.
JP3192067B2 (ja) * 1995-10-09 2001-07-23 科学技術振興事業団 ペプチドとコラーゲン収縮阻害剤
ES2252785T3 (es) 1996-05-16 2006-05-16 THE TEXAS A&M UNIVERSITY SYSTEM Composiciones proteinicas fijadoras de colageno y metodos de utilizacion.
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US20020169108A1 (en) * 1997-05-28 2002-11-14 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20060025348A1 (en) * 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
GB9714276D0 (en) 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US6716963B1 (en) * 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
US7238711B1 (en) * 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
GB9903408D0 (en) * 1999-02-15 1999-04-07 Oxford Biomedica Ltd Peptides
EP1173469A2 (de) * 1999-04-16 2002-01-23 Children's Medical Center Corporation Adhäsions modulierende peptide und verfahren zu deren verwendung
CN1301723A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——纤维结合蛋白类型ii10和编码这种多肽的多核苷酸
AU4243201A (en) * 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
PL364358A1 (en) * 2000-09-07 2004-12-13 Schering Ag Receptor in the edb fibronectin domain (ii)
EP1224943A1 (de) * 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin als Tumor Marker, detektiert durch auf Phagen exprimierte Antikörper
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
US7223390B2 (en) * 2003-05-09 2007-05-29 Research Development Foundation Insertion of furin protease cleavage sites in membrane proteins and uses thereof
US7943294B2 (en) * 2004-07-30 2011-05-17 Hologic, Inc. Methods for detecting oncofetal fibronectin
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
KR20110014199A (ko) 2008-05-13 2011-02-10 클라라산스, 인크. 비강 비염 치료용 재조합 인간 ｃｃ10 및 이의 조성물
WO2010017332A2 (en) * 2008-08-07 2010-02-11 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Radioprotectants targeting thrombospondin-1 and cd47
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
WO2011047065A1 (en) 2009-10-15 2011-04-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza
AU2013246040B2 (en) 2012-04-09 2018-11-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for generation of pluripotent and multipotent cells
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP3125907A4 (de) 2014-04-01 2017-11-29 Cornell University Verwendung von doppelsträngiger dna in exosomen: neuartiger biomarker zur krebsdetektion
FR3024364B1 (fr) 2014-07-31 2016-09-02 Neuronax Oligopeptides particuliers comme medicaments anti-angiogeniques
WO2016057702A2 (en) 2014-10-07 2016-04-14 Cornell University Methods for prognosing and preventing metastatic liver disease
WO2016172710A2 (en) 2015-04-24 2016-10-27 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
SG11202104136YA (en) 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1001013A4 (fr) * 1987-10-22 1989-06-13 Icp Internat Inst Of Cellular Derives de synergimycines de types a et b, procede pour leur preparation et utilisation de ceux-ci.
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
US5190918A (en) * 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin

Also Published As

Publication number Publication date
CA2148383A1 (en) 1994-05-26
EP0669937B1 (de) 1999-08-11
US5849701A (en) 1998-12-15
DE69326016D1 (de) 1999-09-16
JP3789931B2 (ja) 2006-06-28
AU5669594A (en) 1994-06-08
JPH08510715A (ja) 1996-11-12
AU683234B2 (en) 1997-11-06
JP2006028195A (ja) 2006-02-02
US5491130A (en) 1996-02-13
EP0669937A1 (de) 1995-09-06
WO1994011395A1 (en) 1994-05-26
DE69326016T2 (de) 2000-04-13

Similar Documents

Publication Publication Date Title
DE69326016D1 (de) Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen
ATE196428T1 (de) Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen
DE69812630D1 (de) Integrinbindendes peptid und dessen verwendung
ATE172743T1 (de) Nachweis von kollagenabbau -i(in vivo)
ATE548455T1 (de) Zelldurchlässige peptidhemmer des jnk- signaltransduktionsweges
ATE380875T1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
DE59609235D1 (de) Verwendung von aerogelen in der landwirtschaft
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
DK0835447T3 (da) Peptider og sammensætninger, der modulerer apoptose
ES2117123T3 (es) Derivados de aminocetilmercaptoacetilamida utilizados como inhibidores de la encefalinasa y del enzima de conversion de angiotensina.
ATE216400T1 (de) Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle
ATE320488T1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
WO2000048625A3 (en) Inhibitors for use in hemostasis and immune function
ATE191223T1 (de) Verwendung von zelladhäsions-peptiden zur modifikation des haftungsvermögens eukaryontischer zellen untereinander
ATE274351T1 (de) Verwendung von isolierten domänen des type-iv- kollagens zur änderung der zell- und gewebewechselwirkung
MX9304070A (es) Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
NO933423D0 (no) Modifisert blodplate-faktor-4
IT1271486B (it) Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva
Daramola et al. Detection of fibronectin expression by human endothelial cells using a enzyme-linked immunosorbent assay (ELISA): enzymatic degradation by activated plasminogen
MY106261A (en) Anti-inflammatory 1-heteroaryl oxindole-3-carboxamides.
ATE160698T1 (de) Angiogenin und/oder alpha1-microglobulin und/oder komplementfaktor d zur begrenzung der sekretion von proteinen
NO910981L (no) Peptidforbindelser.